原始出處紀錄
狀態:COMPLETED → TERMINATED;primary_completion:2016-12-20 → 2016-12-19;completion:2016-12-20 → 2016-12-19;why_stopped: → 贊助商決定停止 lebrikizumab 用於治療氣喘的開發。;primary_outcomes:['Relative Change From Baseline in Daily OCS Dose at Week 44'] → ['第 44 週時每日口服類固醇 (OCS) 劑量相較於基線的百分比變化'];countries:{'total_sites': 71, 'us_sites': 9} → {'total_sites': 45, 'us_sites': 2}